Evidence map›Paper›PMID 34293084›Full record

ArticleArchives of pathology & laboratory medicine2022

Role of Flow Cytometric Immunophenotyping for Classic Hodgkin Lymphoma in Small Biopsy and Cytology Specimens.

Alexander Chan, Jose Victor Scarpa Carniello, Qi Gao, Allison Sigler, Jeeyeon Baik, Mikhail Roshal, Oscar Lin

Open access · diamondAbstract read
In one paragraph

Article in Archives of pathology & laboratory medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Flow Cytometry for Non-Hodgkin and Hodgkin Lymphomas.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Alexander ChanFrom the Hematopathology (Chan, Gao, Sigler, Baik, Roshal, Lin), Memorial Sloan Kettering Cancer Center, New York, New York.
Jose Victor Scarpa CarnielloCytopathology (Scarpa Carniello, Lin) Services, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Qi GaoFrom the Hematopathology (Chan, Gao, Sigler, Baik, Roshal, Lin), Memorial Sloan Kettering Cancer Center, New York, New York.
Allison SiglerFrom the Hematopathology (Chan, Gao, Sigler, Baik, Roshal, Lin), Memorial Sloan Kettering Cancer Center, New York, New York.
Jeeyeon BaikFrom the Hematopathology (Chan, Gao, Sigler, Baik, Roshal, Lin), Memorial Sloan Kettering Cancer Center, New York, New York.
Mikhail RoshalFrom the Hematopathology (Chan, Gao, Sigler, Baik, Roshal, Lin), Memorial Sloan Kettering Cancer Center, New York, New York.
Oscar LinFrom the Hematopathology (Chan, Gao, Sigler, Baik, Roshal, Lin), Memorial Sloan Kettering Cancer Center, New York, New York.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

CONTEXT.—: The diagnosis of classic Hodgkin lymphoma (CHL) traditionally requires surgical tissue biopsy because of the paucity of diagnostic Hodgkin and Reed-Sternberg cells. Diagnosis can be challenging in small core needle and cytologic biopsies, which are increasingly used because of reduced costs and minimal invasiveness. Flow cytometric (FC) identification of Hodgkin and Reed-Sternberg cells is possible, but FC test efficacy is not well studied outside of validation settings, especially in small specimens. OBJECTIVE.—: To assess the testing efficacy of FC performed on small biopsy and cytology specimens for the diagnosis of CHL. DESIGN.—: We reviewed 131 patients with CHL and 459 patients without CHL during a 3-year period who underwent a small biopsy procedure, including core biopsy and/or cytology evaluation, with concurrent routine clinical FC testing for CHL, assessing performance of FC in small specimens. RESULTS.—: Evaluating testing efficacy, sensitivity was 95.4% and specificity was 98.2%, whereas positive and negative predictive values were 92.2% and 99.0%, respectively. Although there were more false-positive results than compared with published validation studies, expert review identified distinct diagnostic pitfalls; awareness of these may improve testing efficacy. CONCLUSIONS.—: Although FC diagnosis of CHL was historically considered unfeasible, our findings in a real-world clinical setting suggest that FC adds diagnostic value to small biopsy evaluation, reducing time to treatment, costs, and invasive excisional procedures.

Indexed as

Hodgkin DiseaseBiopsyBiopsy, Large-Core NeedleFlow CytometryHumansImmunophenotypingReed-Sternberg Cells

Identifiers

PMID34293084
PMCPMC9473334
OpenAlexW3184570455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.